THERATECHNOLOGIES INC (THTX) Fundamental Analysis & Valuation

NASDAQ:THTX • CA88338H7040

Current stock price

3.39 USD
0 (0%)
At close:
3.4 USD
+0.01 (+0.29%)
After Hours:

This THTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. THTX Profitability Analysis

1.1 Basic Checks

  • In the past year THTX has reported negative net income.
  • In the past year THTX had a positive cash flow from operations.
  • THTX had negative earnings in each of the past 5 years.
  • THTX had negative operating cash flow in 4 of the past 5 years.
THTX Yearly Net Income VS EBIT VS OCF VS FCFTHTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of THTX (-17.86%) is better than 79.10% of its industry peers.
  • THTX's Return On Invested Capital of 55.37% is amongst the best of the industry. THTX outperforms 99.44% of its industry peers.
Industry RankSector Rank
ROA -17.86%
ROE N/A
ROIC 55.37%
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
THTX Yearly ROA, ROE, ROICTHTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600

1.3 Margins

  • The Operating Margin of THTX (10.05%) is better than 92.35% of its industry peers.
  • THTX's Gross Margin of 77.72% is amongst the best of the industry. THTX outperforms 83.96% of its industry peers.
  • In the last couple of years the Gross Margin of THTX has grown nicely.
Industry RankSector Rank
OM 10.05%
PM (TTM) N/A
GM 77.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
THTX Yearly Profit, Operating, Gross MarginsTHTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. THTX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so THTX is creating value.
  • Compared to 1 year ago, THTX has about the same amount of shares outstanding.
  • Compared to 5 years ago, THTX has less shares outstanding
  • THTX has a worse debt/assets ratio than last year.
THTX Yearly Shares OutstandingTHTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
THTX Yearly Total Debt VS Total AssetsTHTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • THTX has an Altman-Z score of -8.27. This is a bad value and indicates that THTX is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -8.27, THTX is not doing good in the industry: 70.15% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.27
ROIC/WACC4.64
WACC11.93%
THTX Yearly LT Debt VS Equity VS FCFTHTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • A Current Ratio of 0.84 indicates that THTX may have some problems paying its short term obligations.
  • THTX has a Current ratio of 0.84. This is amonst the worse of the industry: THTX underperforms 89.37% of its industry peers.
  • THTX has a Quick Ratio of 0.84. This is a bad value and indicates that THTX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • THTX has a worse Quick ratio (0.65) than 91.23% of its industry peers.
Industry RankSector Rank
Current Ratio 0.84
Quick Ratio 0.65
THTX Yearly Current Assets VS Current LiabilitesTHTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. THTX Growth Analysis

3.1 Past

  • The earnings per share for THTX have decreased by 0.00% in the last year.
  • The Revenue has been growing slightly by 2.19% in the past year.
  • THTX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.31% yearly.
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
Revenue 1Y (TTM)2.19%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%-19.48%

3.2 Future

  • Based on estimates for the next years, THTX will show a very strong growth in Earnings Per Share. The EPS will grow by 29.71% on average per year.
  • THTX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.44% yearly.
EPS Next Y88.56%
EPS Next 2Y66.79%
EPS Next 3Y46.8%
EPS Next 5Y29.71%
Revenue Next Year-3.03%
Revenue Next 2Y5.03%
Revenue Next 3Y5.76%
Revenue Next 5Y3.44%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
THTX Yearly Revenue VS EstimatesTHTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
THTX Yearly EPS VS EstimatesTHTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

Find the best growth stocksShow best growing peers

4

4. THTX Valuation Analysis

4.1 Price/Earnings Ratio

  • THTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 24.08 indicates a rather expensive valuation of THTX.
  • Based on the Price/Forward Earnings ratio, THTX is valued cheaper than 91.79% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.36, THTX is valued at the same level.
Industry RankSector Rank
PE N/A
Fwd PE 24.08
THTX Price Earnings VS Forward Price EarningsTHTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, THTX is valued cheaper than 94.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 18.18
THTX Per share dataTHTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • THTX's earnings are expected to grow with 46.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y66.79%
EPS Next 3Y46.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. THTX Dividend Analysis

5.1 Amount

  • No dividends for THTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

THTX Fundamentals: All Metrics, Ratios and Statistics

THERATECHNOLOGIES INC

NASDAQ:THTX (9/25/2025, 8:03:14 PM)

After market: 3.4 +0.01 (+0.29%)

3.39

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength26.77
Industry Growth11.19
Earnings (Last)07-09
Earnings (Next)10-08
Inst Owners22.29%
Inst Owner Change-99.26%
Ins Owners0.9%
Ins Owner ChangeN/A
Market Cap155.87M
Revenue(TTM)84.38M
Net Income(TTM)-9.16M
Analysts84
Price Target4.09 (20.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-291.26%
Min EPS beat(2)-482.52%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-224.76%
Min EPS beat(4)-482.52%
Max EPS beat(4)94.17%
EPS beat(8)5
Avg EPS beat(8)-62.95%
EPS beat(12)6
Avg EPS beat(12)-46.18%
EPS beat(16)6
Avg EPS beat(16)-49.02%
Revenue beat(2)0
Avg Revenue beat(2)-5.7%
Min Revenue beat(2)-9.5%
Max Revenue beat(2)-1.91%
Revenue beat(4)1
Avg Revenue beat(4)-3.24%
Min Revenue beat(4)-9.5%
Max Revenue beat(4)6.97%
Revenue beat(8)1
Avg Revenue beat(8)-5.3%
Revenue beat(12)1
Avg Revenue beat(12)-6.15%
Revenue beat(16)1
Avg Revenue beat(16)-7.55%
PT rev (1m)0.63%
PT rev (3m)-1.02%
EPS NQ rev (1m)-166.67%
EPS NQ rev (3m)-125%
EPS NY rev (1m)0%
EPS NY rev (3m)-124%
Revenue NQ rev (1m)-7.92%
Revenue NQ rev (3m)-10.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 24.08
P/S 1.85
P/FCF N/A
P/OCF 22.15
P/B N/A
P/tB N/A
EV/EBITDA 18.18
EPS(TTM)-0.19
EYN/A
EPS(NY)0.14
Fwd EY4.15%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)0.15
OCFY4.51%
SpS1.84
BVpS-0.61
TBVpS-0.98
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -17.86%
ROE N/A
ROCE 70.09%
ROIC 55.37%
ROICexc 307.38%
ROICexgc N/A
OM 10.05%
PM (TTM) N/A
GM 77.72%
FCFM N/A
ROA(3y)-32.34%
ROA(5y)-29.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.54%
GM growth 5Y5.34%
F-Score4
Asset Turnover1.65
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 3.84
Cap/Depr 519.63%
Cap/Sales 11.98%
Interest Coverage 1.21
Cash Conversion 67.47%
Profit Quality N/A
Current Ratio 0.84
Quick Ratio 0.65
Altman-Z -8.27
F-Score4
WACC11.93%
ROIC/WACC4.64
Cap/Depr(3y)39.02%
Cap/Depr(5y)23.86%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-550%
EPS Next Y88.56%
EPS Next 2Y66.79%
EPS Next 3Y46.8%
EPS Next 5Y29.71%
Revenue 1Y (TTM)2.19%
Revenue growth 3Y7.14%
Revenue growth 5Y6.31%
Sales Q2Q%-19.48%
Revenue Next Year-3.03%
Revenue Next 2Y5.03%
Revenue Next 3Y5.76%
Revenue Next 5Y3.44%
EBIT growth 1Y125.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.1%
EBIT Next 3Y43.2%
EBIT Next 5Y28.68%
FCF growth 1Y82.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.06%
OCF growth 3YN/A
OCF growth 5YN/A

THERATECHNOLOGIES INC / THTX Fundamental Analysis FAQ

What is the fundamental rating for THTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to THTX.


Can you provide the valuation status for THERATECHNOLOGIES INC?

ChartMill assigns a valuation rating of 4 / 10 to THERATECHNOLOGIES INC (THTX). This can be considered as Fairly Valued.


How profitable is THERATECHNOLOGIES INC (THTX) stock?

THERATECHNOLOGIES INC (THTX) has a profitability rating of 4 / 10.


How financially healthy is THERATECHNOLOGIES INC?

The financial health rating of THERATECHNOLOGIES INC (THTX) is 1 / 10.


What is the earnings growth outlook for THERATECHNOLOGIES INC?

The Earnings per Share (EPS) of THERATECHNOLOGIES INC (THTX) is expected to grow by 88.56% in the next year.